Plain-English translation of NCT05992220 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining two immunotherapy medications called atezolizumab and bevacizumab — along with external beam radiation therapy — works better than using just the two medications alone for advanced liver cancer that has spread into blood vessels. About 138 people will be randomly assigned to receive either the medication combination by itself, or the same medications plus targeted radiation therapy to the affected area.
Advanced liver cancer that invades blood vessels is very difficult to treat and has limited treatment options. Researchers want to see whether adding radiation therapy to this immunotherapy combination might help the body's immune system fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You will visit the study center regularly to receive intravenous infusions of the two medications every three weeks. Depending on which group you are randomly assigned to, you may also receive external beam radiation therapy starting after your first round of medications. Each treatment cycle lasts 21 days, and you will continue receiving treatment as long as the cancer responds and side effects are manageable. The study team will monitor your health closely with blood tests and imaging scans throughout your participation.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
South Korea